US based drug company, Vivus Inc has entered into a settlement agreement with Dr.Reddy’s Labs. This is to finally bring an end to the long drawn battle on patent litigation, pending since 2015; this pertained to its weight management capsule, Qsymia.

Dr.Reddy’s had submitted an Abbreviated New drug Application (ANDA) wherein it sought approval to market generic versions of Qsymia.

This settlement with Vivus now allows Dr.Reddy’s to begin selling this generic version from June 2025 or earlier under certain circumstances. If an early launch happens, Vivus will receive a royalty on sales of the generic version of the drug.

This settlement concludes all patent litigation brought by Vivus against generic pharma companies that have filed Andas seeking approval to market generic versions of Qsymia.

Not surprisingly, Dr.Reddy’s opened amongst the top three gainers on the BSE, zooming up almost 7.5% to Rs.2169.